CROSSJECT's Growing Collaboration with ETON PHARMACEUTICALS
CROSSJECT is excited to announce an enhancement in its partnership with ETON PHARMACEUTICALS, Inc. This collaboration revolves around the groundbreaking hydrocortisone formulation, aimed at entering the hospital adrenal insufficiency market. By working together, CROSSJECT has positioned itself to earn a high-single digit royalty on the net sales generated by ETON.
Targeting a Multi-Million Dollar Market
With a firm commitment to developing and manufacturing its adrenal insufficiency product line, ETON is moving forward with both the CROSSJECT formulation, known as ET-800, and the revolutionary product, ZENEO® Hydrocortisone. This initiative aims to seize a robust market opportunity, anticipated to be worth over $200 million in the U.S. alone.
Product Development Timeline
Looking ahead, product filings are expected to commence from the second half of 2026. This strategic timeline sets a clear path for the release of life-changing products aimed at treating adrenal insufficiency.
Innovation in Formulation
CROSSJECT has developed a unique and proprietary ready-to-use liquid formulation of hydrocortisone. In contrast to existing solutions that require intricate steps for reconstitution, this innovative formulation simplifies the process, making it accessible for healthcare settings. As such, ETON will commercialize this CROSSJECT Formulation as a more effective alternative to currently available injectables in the market.
CROSSJECT's Vision and Commitment
Pablo_CONTACT_DEVELOPMENT, the CEO of CROSSJECT, expressed gratitude for ETON's positive feedback regarding the value contributed by CROSSJECT. This collaboration not only showcases CROSSJECT's expertise in complex injectable formulations but also highlights their ongoing dedication to advancing solutions for patients facing adrenal insufficiency crises.
Future Prospects and Market Evaluation
ETON’s recent investor presentation affirmed its strong commitment to the ZENEO® Hydrocortisone product, envisaging its role as a transformative solution for crises related to adrenal insufficiency. The anticipated market potential for ZENEO® Hydrocortisone surpasses $100 million, which both companies are actively working to capitalize on.
About CROSSJECT
CROSSJECT SA is a pioneering specialty pharmaceuticals company dedicated to developing medicines for emergent medical situations utilizing its esteemed needle-free auto-injector ZENEO® platform. Currently, CROSSJECT is in advanced regulatory phases for ZEPIZURE®, an emergency injectable treatment for epilepsy, backed by a significant contract aimed at advancing U.S. public health safety. The company’s product pipeline is diverse, including solutions not just for adrenal insufficiencies but also for allergic responses.
About ETON PHARMACEUTICALS
ETON PHARMACEUTICALS stands at the forefront of innovation in the pharmaceutical landscape, focusing on the development and commercialization of treatments specifically for rare diseases. ETON’s portfolio includes several commercial rare disease products and additional candidates in late-stage development, reinforcing their commitment to addressing significant, yet often overlooked, medical challenges.
Frequently Asked Questions
What are the main goals of the CROSSJECT and ETON partnership?
The main goal is to develop innovative solutions for adrenal insufficiency, particularly through the CROSSJECT Formulation and ZENEO® Hydrocortisone.
How does the new hydrocortisone formulation differ from existing products?
This new formulation is ready-to-use and eliminates the need for complex reconstitution, making it more user-friendly for healthcare providers.
When can we expect the product filings to begin?
Product filings are anticipated to start from the second half of 2026.
What is CROSSJECT's broader mission?
CROSSJECT aims to develop emergency medications that can be administered easily, especially in urgent situations.
How can I get more information about CROSSJECT?
For further inquiries, you can reach out to CROSSJECT's investor relations via email at investors@crossject.com.
